RxDoctor Payments Data

Sarah Maclaurin

Psychiatric/Mental Health · Boston, MANPI 1104057918

Payments from drug & device makers

$2,913in general payments, 2019–2025

Across 13 payments — averaging $224.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Alkermes, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$75
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$65
  • Indivior Inc.$34
  • AbbVie$22
  • plus $17 from 1 others

What the payments were for

  • Consulting fees$2,57088%
  • Food & beverage$1967%
  • Education$1475%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,913 in reported general payments places this provider in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$83,835
Medicare patients
89
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole137$369,771
AristadaAripiprazole Lauroxil72$201,802
Invega SustennaPaliperidone Palmitate48$137,996
Invega TrinzaPaliperidone Palmitate14$119,275
CaplytaLumateperone Tosylate34$57,858
UzedyRisperidone14$56,897
Clozapine647$41,606
VraylarCariprazine Hcl22$38,011
Clozapine OdtClozapine78$28,260
LybalviOlanzapine/Samidorphan Malate14$22,795
Varenicline Tartrate42$11,723
Olanzapine311$6,255
Divalproex Sodium ErDivalproex Sodium75$4,425
Aripiprazole147$3,988
Divalproex Sodium66$3,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$1,420$257,27162 claims
Alkermes, Inc.Aristada, Lybalvi$1,279$224,59786 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$65$57,85834 claims
Teva Pharmaceuticals USA, Inc.Uzedy$75$56,89714 claims
AbbVieVraylar$22$38,01122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →